Researchers assessed 13,276 patients with chronic myeloid leukemia to characterize the incidence and types of second malignancies in this patient population.
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
An interesting finding from this study was that many of the reasons offered by patients either in support of or against TKI discontinuation related to the same topic areas.
Treatment-free remission maintained in 14 of 21 patients who discontinued tyrosine kinase inhibitors.
A retrospective study using a cohort of the ALiCCS Study sought to determine hospitalization risks among survivors of leukemia during childhood 20 years after diagnosis.